In the pre-PSA-detection era, a large proportion of men were diagnosed with metastatic
prostate cancer and died of the disease; after the introduction of the serum PSA test …

In recent years, several new biomarkers supplementing the role of prostate-specific antigen
(PSA) have become available for men with prostate cancer. Although widely used in an ad …

Purpose: The Prostate Health Index (phi) is a new test combining total, free and [-2] proPSA
into a single score. It was recently approved by the FDA and is now commercially available …

Purpose: Prostate specific antigen and free prostate specific antigen have limited specificity
to detect clinically significant, curable prostate cancer, leading to unnecessary biopsy, and …

Prostate cancer (PC) is one of the most common tumors and a leading cause of mortality
among men, resulting in~ 375 000 deaths annually worldwide. Various analytical methods …

Background The four-kallikrein panel and the Prostate Health Index (PHI) have been shown
to improve prediction of prostate cancer (PCa) compared with prostate-specific antigen …

Purpose: We evaluated the ability of PHI to discriminate aggressive prostate cancer from
indolent or no cancer in a biopsy naïve population. Materials and Methods: Two …

BACKGROUND: Strategies to reduce prostate-specific antigen (PSA)–driven prostate
cancer (PCa) overdiagnosis and overtreatment seem to be necessary. OBJECTIVE: To test …

Background Total prostate-specific antigen (tPSA), ratio of free PSA (fPSA) to tPSA (% fPSA),
and PSA density (PSAD) testing have a very low accuracy in the detection of prostate cancer …

Abstract The usefulness of%[− 2] proPSA and Prostate Health Index (phi) in the detection of
prostate cancer are currently unknown. It has been suggested that these tests can …